PCM
BXRX

Prelude Capital Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Prelude Capital Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1
Closed -$4.53K – 2542
2020
Q2 		$5K Buy
+1
New +$4.8K ﹤0.01% 1732

Other funds holding BXRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's BXRX Position: Q3 2020 in Review

Prelude Capital Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q3 2020, closing a stake of 1 share — an estimated $4.53K sold.

Prelude Capital Management first reported a position in BXRX in Q2 2020 and held it in 1 quarter. The position peaked at $5K in Q2 2020. 26 funds tracked by Wall St. Rank hold BXRX as of Q3 2020.

  • Prelude Capital Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 1 Baudax Bio, Inc. Common Stock share in Q3 2020, an estimated $4.53K.
  • Prelude Capital Management first reported a position in Baudax Bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Prelude Capital Management's Baudax Bio, Inc. Common Stock position peaked at $5K in Q2 2020.
  • 26 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.